Compositions for treating sorafenib-resistant liver cancer and Methods for providing information on treating sorafenib-resistant liver cancer

摘要

The present invention relates to a composition for treating sorafenib-resistant liver cancer and a method for providing information on the treatment of sorafenib-resistant liver cancer, and more particularly, to a composition for treating sorafenib-resistant liver cancer containing NK cells, and a sora having reduced CEACAM1 expression It relates to a method of providing information on the treatment of liver cancer, comprising the step of providing information on the effect of administering NK cells to a phenib-resistant liver cancer patient. In the present invention, it was confirmed that CEACAM1 expression was decreased in SR-Huh7 cells having sorafenib resistance. In particular, when NK cells treated with anti-CEACAM1 antibody and SR-Huh7 cells were co-cultured, NK cells Since it was confirmed that the SR-Huh7 cytotoxic effect was increased, the administration regimen of NK cells can be effectively applied to the treatment of sorafenib-resistant liver cancer.